Amgen Inc.

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Founded in 1980, Amgen's core business involves the discovery, development, manufacturing, and delivery of innovative human therapeutics. Its mission is to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives.

The company focuses on four primary therapeutic areas: general medicine, rare diseases, inflammation, and oncology/hematology, including cardiovascular and bone diseases. Key products in its portfolio include Prolia, XGEVA, Enbrel, Repatha, Otezla, Tepezza, Evenity, Kyprolis, Nplate, and Lumakras, addressing a wide range of serious illnesses. Amgen leverages advanced science and technology, including genetic and protein engineering, to develop its medicines and operates in approximately 100 countries worldwide.

Robert A. Bradway serves as the Chairman and Chief Executive Officer. Amgen reported strong financial results for the first quarter of 2026, with 16 brands achieving double-digit growth. Recent strategic moves include the acquisition of Horizon Therapeutics for $27.8 billion in October 2023 and ChemoCentryx for $3.7 billion in October 2022, expanding its rare disease portfolio. The company continues to advance a robust pipeline, notably including MariTide, an investigational anti-obesity medication. Amgen is recognized as a leading biopharmaceutical firm, ranked among the largest biomedical companies by revenue, and was added to the Dow Jones Industrial Average in 2020.